A new The Scientist feature revisits the long, strange history of Annovis’ lead drug candidate as its Phase 3 Alzheimer’s trial moves forward.
Phase 3 clinical-stage biotech Annovis Bio has published a historical review in The Scientist titled “Buntanetap: From Execution Poison to Potential Alzheimer’s Disease Drug,” offering a sweeping look at the origins of its lead candidate, buntanetap, just as the company continues enrolling patients in late-stage Alzheimer’s and Parkinson’s studies [1]. The timing makes it more than just a public announcement.
Annovis is building narrative weight around a late-stage neurodegeneration asset at a moment when clinical progress matters more than ever. The company says its pivotal Phase 3 study in early Alzheimer’s disease is now 70% enrolled, while its open-label extension study in Parkinson’s disease is 20% enrolled. In a field littered with disappointment, that kind of progress invites a bigger question: why should investors and longevity watchers pay attention now?
Annovis’ answer, it seems, is that buntanetap did not arrive overnight. It survived a long process of refinement, failure, reinterpretation and scientific stubbornness – all of which may make it more interesting, not less.
The feature leans into the almost surreal origin story. Buntanetap traces its roots back to the Calabar bean, a toxic seed associated with 19th-century “trial by ordeal” practices in parts of West Africa. Over time, scientists isolated its active compound, physostigmine, which eventually found medical use. Decades later, researchers began exploring whether derivatives of that same chemistry might help in neurodegenerative disease.
That path led to phenserine, and then to posiphen – the compound that later became buntanetap.
If that sounds like an odd route to an Alzheimer’s drug, it is. However, it is also a useful reminder that drug development is rarely a clean, linear story. More often, it looks like a relay race in which one generation of researchers hands off an imperfect molecule to the next, hoping someone else can make it safer, smarter and more relevant.
That may be the real subtext of Annovis’ announcement. In biotech, especially in Alzheimer’s, a failed predecessor can kill enthusiasm for years. Annovis is making the opposite argument, that sometimes what looks like failure is really the rough draft.
Annovis describes buntanetap as an investigational once-daily oral therapy designed to reduce the production of several neurotoxic proteins linked to diseases like Alzheimer’s and Parkinson’s.
Think of the aging brain as a house where multiple leaks have started at once. One pipe is dripping, another is cracked and the wiring is beginning to spark. Much of modern drug development has tried to fix one leak at a time. Buntanetap, at least in theory, is trying to get closer to the main valve.
Instead of targeting a single harmful protein associated with Alzheimer’s, Annovis is positioning the drug as a broader approach to slow the production of several proteins that can accumulate and damage brain cells over time. The company says these include proteins tied to Alzheimer’s and Parkinson’s pathology. That broader approach matters because neurodegeneration rarely behaves like a single-cause disease. It is more like a slow systems breakdown. Messy, overlapping and deeply tied to aging itself.
The story is especially relevant to longevity. The longevity field has increasingly outgrown the idea that aging can be understood through one biomarker, one pathway or one silver bullet. Alzheimer’s is perhaps the clearest example. It is not simply a “memory disease.” It is one of the harshest expressions of what happens when resilience, repair and cellular housekeeping all begin to fail at once.
A drug that aims to intervene upstream – before multiple kinds of damage pile up – naturally fits that wider conversation.
“Buntanetap is the product of more than a century and a half of pharmacological refinement and clinical learning,” said Dr Alexander Morin, Director of Strategic Communications at Annovis. “This article is an opportunity to share that story in accessible language, tracing the key moments that have brought buntanetap to where it stands today. It also reflects Annovis’ commitment to scientific transparency and education as we approach important clinical and regulatory milestones [2].”
For a Phase 3-stage company, “transparency and education” can also function as a kind of market signaling. Alzheimer’s investors have been trained to be skeptical and for good reason. This is one of biotech’s most punishing categories, where exciting mechanisms often collide with clinical reality. By placing buntanetap’s history in The Scientist, Annovis is trying to frame it as a serious, evolved asset rather than another speculative swing.
There is a subtle confidence in that. Instead of shouting breakthrough, the company is telling a longer story that this molecule has been revised, rethought and stress-tested over time. That can be a surprisingly persuasive message.
Truly, the sector loves the language of disruption – new platforms, AI-designed molecules, fresh targets. But sometimes progress comes from revisiting old science with better tools and better questions. Buntanetap’s story suggests that not every discarded compound deserves to stay discarded. Sometimes, the molecule was early. Sometimes, the framing was wrong. Sometimes, the field had not yet learned how to read the biology.
If buntanetap succeeds, it will be both an Alzheimer’s story and a longevity story about persistence: about extending brain healthspan not through a flashy one-off invention, but through decades of refinement aimed at slowing the biological chaos that comes with age.
[1] https://www.the-scientist.com/buntanetap-from-execution-poison-to-potential-alzheimer-s-disease-drug-74274
[2] https://www.annovisbio.com/press-release/annovis-publishes-historical-review-of-buntanetap-in-the-scientist
